Document Detail

Role of taurine in spinal cord injury.
MedLine Citation:
PMID:  16918386     Owner:  NLM     Status:  MEDLINE    
Taurine is a sulfur amino acid. It is found endogenously in human and several others tissues. It is significantly in high concentration in mammals. Human body contains about 0.1% of body weight as taurine. It has a number of physiological and pharmacological actions. It is also used in the therapy of important organs dysfunctions. In spinal cord it has inhibitory effects; like antiepileptic and anti-nociceptive. Taurine also inhibits substance p induced biting and scratching behavior. In spinal cord injury elevated level of taurine has been observed. Higher level of taurine has been also recorded in SCI therapy using, known clinical agent methyl prednisolone (MP). The increased taurine concentration seems to be involved in protection and regeneration of tissues following injury. In SCI along with physical injury secondary activities also takes place which are complex in nature. Secondary activity includes vascular events and activation of neutrophils, resulting endothelial damage. Activated neutrophils; release a variety of inflammatory mediators such as myeloperoxidase (MPO), reactive oxygen species (ROS), and some others. It is believed that taurine exert its protective action through scavenging of ROS and down regulating several other inflammatory mediators like tumor necrosis factors (TNFalpha). The inside of mechanism reveals toxic substance HOCl is produced by MPO is converted to less toxic substances through scavenging action of taurine. Amino acid therapy has its own limitations and to over come such situation there is a need to develop small, simple lipophilic analogs of taurine. Use of taurine analogs has provided better results; for example, N- chloro taurine (NCT) which is a taurine derivative has exhibited therapeutic advances over taurine. Taurine and its analogs with sound experimental and clinical support may constitute a new class of therapeutic agents for SCI., and perhaps this review may provide enough material to think of this.
R C Gupta; Y Seki; J Yosida
Related Documents :
22034486 - Authors' response: on sialic acid transport and utilization by vibrio cholerae.
21918036 - Monomethylarsenic diglutathione [mmaiii(gs)2] transport by the human multidrug resistan...
16081116 - Isolation and absolute configuration of new bioactive marine steroids from euryspongia ...
19444866 - Inhibitory effects on bacterial growth and beta-ketoacyl-acp reductase by different spe...
2610366 - Simultaneous determination of ascorbic acid, caffeine and paracetamol in drug formulati...
6874586 - Leptomycins a and b, new antifungal antibiotics. ii. structure elucidation.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current neurovascular research     Volume:  3     ISSN:  1567-2026     ISO Abbreviation:  -     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-08-21     Completed Date:  2006-10-18     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  101208439     Medline TA:  Curr Neurovasc Res     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  225-35     Citation Subset:  IM    
SASRD, Nagaland University, Medziphema 797106, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Methylprednisolone / pharmacology
Neuroprotective Agents / pharmacology
Neutrophils / drug effects,  immunology
Reactive Oxygen Species / metabolism
Signal Transduction / drug effects*
Spinal Cord Injuries / drug therapy,  metabolism*,  physiopathology
Taurine* / metabolism,  pharmacology
Reg. No./Substance:
0/Neuroprotective Agents; 0/Reactive Oxygen Species; 107-35-7/Taurine; 83-43-2/Methylprednisolone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Implications of prion protein biology.
Next Document:  New vessel formation in the central nervous system during tumor growth, vascular malformations, and ...